Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to...
| Autores: | ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; |
|---|---|
| Tipo de documento: | Artículo |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Servizo Galego de Saúde (SERGAS) |
| Repositorio: | RUNA. Repositorio da Consellería de Sanidade e Sergas |
| OAI Identifier: | oai:runa.sergas.gal:20.500.11940/21365 |
| Acceso en línea: | https://portalcientifico.sergas.gal//documentos/640d5f72f0c92964f8440b28 http://hdl.handle.net/20.500.11940/21365 |
| Nivel de acceso: | Acceso abierto |
| Palabra clave: | Humans COVID-19 Spain Retrospective Studies Lamivudine Pandemics HIV Infections AS Pontevedra CHUP |
| _version_ | 1878741901433110528 |
|---|---|
| author | Buzón, L. |
| author2 | Dueñas, C. Pedrero, R. Iribarren, J.A. de Los Santos, I. Díaz de Santiago, A. Morán, M.Á. Pousada Fernández, Guillermo Moreno, E. Ferreira, E. Iglesias, A. Martín, C. Gómez, J. Rodríguez, L. Egido, M. Sepulveda, M.-A. Troya, J. |
| author2_role | author author author author author author author author author author author author author author author author |
| author_browse | Buzón, L. Dueñas, C. Díaz de Santiago, A. Egido, M. Ferreira, E. Gómez, J. Iglesias, A. Iribarren, J.A. Martín, C. Moreno, E. Morán, M.Á. Pedrero, R. Pousada Fernández, Guillermo Rodríguez, L. Sepulveda, M.-A. Troya, J. de Los Santos, I. |
| author_facet | Buzón, L. Dueñas, C. Pedrero, R. Iribarren, J.A. de Los Santos, I. Díaz de Santiago, A. Morán, M.Á. Pousada Fernández, Guillermo Moreno, E. Ferreira, E. Iglesias, A. Martín, C. Gómez, J. Rodríguez, L. Egido, M. Sepulveda, M.-A. Troya, J. |
| author_role | author |
| collection | RUNA. Repositorio da Consellería de Sanidade e Sergas |
| description | Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to DTG+3TC from 13 Spanish hospitals. DTG+3TC provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. The analysis for paired data showed an increase in CD4+ cell count. A statistically significant increase in CD4+ lymphocyte count was found in those without comorbidities in the three-time series analyzed [average increase at 24 weeks: 48.7 (SD: 215.3) vs. 25.8 (SD: 215.5), p-value = 0.050; a mean increase at 48 weeks: 75.1 (SD: 232.9) vs. 42.3 (SD: 255.6), p-value = 0.003; a mean increase at 96 weeks: 120.1 (SD: 205.0) vs. 63.8 (SD:275.3), p-value = 0.003]. In conclusion, our cohort demonstrates that DTG+3TC is an effective treatment strategy for virologically-suppressed PLWHIV independent of age, sex, and HIV stage, as well as a safe and durable strategy. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_ed1db32c7b5d5b46f0200e68db800167 |
| institution | Servizo Galego de Saúde (SERGAS) |
| instname_str | Servizo Galego de Saúde (SERGAS) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:runa.sergas.gal:20.500.11940/21365 |
| publishDate | 2023 |
| publishDateSort | 2023 |
| reponame_str | RUNA. Repositorio da Consellería de Sanidade e Sergas |
| spelling | Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic Buzón, L. Dueñas, C. Pedrero, R. Iribarren, J.A. de Los Santos, I. Díaz de Santiago, A. Morán, M.Á. Pousada Fernández, Guillermo Moreno, E. Ferreira, E. Iglesias, A. Martín, C. Gómez, J. Rodríguez, L. Egido, M. Sepulveda, M.-A. Troya, J. Humans COVID-19 Spain Retrospective Studies Lamivudine Pandemics HIV Infections AS Pontevedra CHUP Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to DTG+3TC from 13 Spanish hospitals. DTG+3TC provided high rates of undetectable viral load over 96%, corresponding to 96.6% (889/921) at 24 weeks, 97.5% (743/763) at 48 weeks, and 98.3% (417/425) at 96 weeks. No significant differences are evident when comparing the total population according to sex, presence of comorbidity, or presence of AIDS. The analysis for paired data showed an increase in CD4+ cell count. A statistically significant increase in CD4+ lymphocyte count was found in those without comorbidities in the three-time series analyzed [average increase at 24 weeks: 48.7 (SD: 215.3) vs. 25.8 (SD: 215.5), p-value = 0.050; a mean increase at 48 weeks: 75.1 (SD: 232.9) vs. 42.3 (SD: 255.6), p-value = 0.003; a mean increase at 96 weeks: 120.1 (SD: 205.0) vs. 63.8 (SD:275.3), p-value = 0.003]. In conclusion, our cohort demonstrates that DTG+3TC is an effective treatment strategy for virologically-suppressed PLWHIV independent of age, sex, and HIV stage, as well as a safe and durable strategy. https://portalcientifico.sergas.gal//documentos/640d5f72f0c92964f8440b28 http://hdl.handle.net/20.500.11940/21365 |
| spellingShingle | Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic Buzón, L. Humans COVID-19 Spain Retrospective Studies Lamivudine Pandemics HIV Infections AS Pontevedra CHUP |
| title | Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic |
| title_full | Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic |
| title_fullStr | Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic |
| title_full_unstemmed | Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic |
| title_short | Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic |
| title_sort | Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic |
| topic | Humans COVID-19 Spain Retrospective Studies Lamivudine Pandemics HIV Infections AS Pontevedra CHUP |
| topic_facet | Humans COVID-19 Spain Retrospective Studies Lamivudine Pandemics HIV Infections AS Pontevedra CHUP |
| url | https://portalcientifico.sergas.gal//documentos/640d5f72f0c92964f8440b28 http://hdl.handle.net/20.500.11940/21365 |